Gerard L. Brien

Gerard L. Brien

Auto-generated profile, based on publicly available information

Gerard L. Brien

Smurfit Institute of Genetics, Trinity College Dublin, Dublin, Ireland.

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2012 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
GBGerard L Brien
Gerard L Brien
GGGuillermo Gambero
Guillermo Gambero
DOdavid o'connell
david o'connell
EJEmilia Jerman
Emilia Jerman
STSiobhán A Turner
Siobhán A Turner
ABAdrian P Bracken
Adrian P Bracken

15 November 2018 in eLife
Verified
Journal Article
Open access
GBGerard L Brien
Gerard L Brien
DRDavid Remillard
David Remillard
JSJunwei Shi
Junwei Shi
MHMatthew L Hemming
Matthew L Hemming
JCJonathon Chabon
Jonathon Chabon
SAScott A Armstrong
Scott A Armstrong
Synovial sarcoma tumours contain a characteristic fusion protein, SS18-SSX, which drives disease development. Targeting oncogenic fusion proteins presents an attractive therapeutic opportunity. However, SS18-SSX has proven intractable for therapeutic intervention. Using a domain-focused CRISPR screen we identified the bromodomain of BRD9 as a critical functional dependency in synovial sarcoma. BRD9 is a component of SS18-SSX containing BAF complexes in synovial sarcoma cells; and integration of BRD9 into these complexes is critical for cell growth. Moreover BRD9 and SS18-SSX co-localize extensively on the synovial sarcoma genome. Remarkably, synovial sarcoma cells are highly sensitive to a novel small molecule degrader of BRD9, while other sarcoma subtypes are unaffected. Degradation of BRD9 induces downregulation of oncogenic transcriptional programs and inhibits tumour progression in vivo. We demonstrate that BRD9 supports oncogenic mechanisms underlying the SS18-SSX fusion in synovial sarcoma and highlight targeted degradation of BRD9 as a potential therapeutic opportunity in this disease.

1 April 2016 in Cancer Cell
Verified
Journal Article
Closed access
GBGerard L. Brien
Gerard L. Brien
DVDaria G. Valerio
Daria G. Valerio
SAScott A. Armstrong
Scott A. Armstrong

1 December 2016 in Cancer Cell
Verified
Journal Article
Closed access
HXHaiming Xu
Haiming Xu
DVDaria G. Valerio
Daria G. Valerio
MEMeghan E. Eisold
Meghan E. Eisold
ASAmit Sinha
Amit Sinha
RKRichard P. Koche
Richard P. Koche
SAScott A. Armstrong
Scott A. Armstrong

1 November 2016 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
GOGiorgio Oliviero
Giorgio Oliviero
GBGerard L. Brien
Gerard L. Brien
AWAriane Waston
Ariane Waston
GSGundula Streubel
Gundula Streubel
EJEmilia Jerman
Emilia Jerman
GCGerard Cagney
Gerard Cagney
Polycomb proteins assemble to form complexes with important roles in epigenetic regulation. The Polycomb Repressive Complex 2 (PRC2) modulates the di- and tri-methylation of lysine 27 on histone H3, each of which are associated with gene repression. Although three subunits, EZH1/2, SUZ12, and EED, form the catalytic core of PRC2, a wider group of proteins associate with low stoichiometry. This raises the question of whether dynamic variation of the PRC2 interactome results in alternative forms of the complex during differentiation. Here we compared the physical interactions of PRC2 in undifferentiated and differentiated states of NTERA2 pluripotent embryonic carcinoma cells. Label-free quantitative proteomics was used to assess endogenous immunoprecipitation of the EZH2 and SUZ12 subunits of PRC2. A high stringency data set reflecting the endogenous state of PRC2 was produced that included all previously reported core and associated PRC2 components, and several novel interacting proteins. Comparison of the interactomes obtained in undifferentiated and differentiated cells revealed candidate proteins that were enriched in complexes isolated from one of the two states. For example, SALL4 and ZNF281 associate with PRC2 in pluripotent cells, whereas PCL1 and SMAD3 preferentially associate with PRC2 in differentiating cells. Analysis of the mRNA and protein levels of these factors revealed that their association with PRC2 correlated with their cell state-specific expression. Taken together, we propose that dynamic changes to the PRC2 interactome during differentiation may contribute to directing its activity during cell fate transitions.

8 April 2019 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
GBGerard L. Brien
Gerard L. Brien
KSKimberly Stegmaier
Kimberly Stegmaier
SAScott A. Armstrong
Scott A. Armstrong